| Literature DB >> 29562634 |
Cui-Yu Ba1,2, Xiao-Yan Du3, Pei-Jun Zhang4, Ping Chen5, Ya-Nan Cai6, Yue-Hong Li7,8.
Abstract
The present study aimed to identify differentially expressed genes (DEGs) and major signal transduction pathways that were related to the immune response of epithelioma papulosum cyprinid (EPC) cells to reoviruses isolated from allogynogenetic silver crucian carp. The study also lays a theoretical foundation for the pathogenesis and immunity of the reovirus, which is helpful to the breeding of cyprinids fish. Reovirus infected and uninfected EPC cells were analyzed by using a new-generation high-throughput sequencing technology. DEGs were identified, annotated, and classified, and the signal pathways involved in the response to reovirus infection were identified by using bioinformatics tool. The data were assembled into 92,101 contigs with an average length of 835.24 bp and an N50 value of 1432 nt. Differential expression analysis of all the genes identified 3316 DEGs at a false discovery rate (FDR) of <0.01 and a fold-change of ≥3, of which 1691 were upregulated genes, 1625 were downregulated, and about 305 were immune-related genes. Gene Ontology (GO) enrichment analysis resulted in the annotation of 3941 GO terms, including 2719 biological processes (37,810 unigenes), 376 cell components (7943 unigenes), and 846 molecular functions (11,750 unigenes). KEGG metabolic pathway analysis matched the DEGs from pre-and post-infection EPC cells to 193 pathways, of which 35 were immune-related, including the Toll-like receptor, cytokine-cytokine receptor interaction, and the JAK-STAT signaling pathways.Entities:
Keywords: EPC; allogynogenetic silver crucian carp; reovirus; transcriptome
Mesh:
Year: 2018 PMID: 29562634 PMCID: PMC5869528 DOI: 10.3390/v10030135
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Cytopathy of epithelioma papulosum cyprinid (EPC) cells after virus infection (100×).
Primers, sequences, target genes, product sizes, and applications used in the present study.
| Name | Sequence (5′ → 3′) | Product Size (bp) |
|---|---|---|
| IL-11F | TAGAGCACTGCTAGGCCTGA | 124 |
| IL-11R | TACCACGATGCCTGTTGACC | |
| MYD88F | GAGGACAGTCGCCGAAATGA | 123 |
| MYD88R | TTTGCTACAGTGGCCTCTGG | |
| P38F | CTTTCTTCCCACTCGCTGGT | 146 |
| P38R | AATCCCTCTGCTTGTCTGCC | |
| HSP90F | ATGGTGGAGTTGTCTCGCAG | 127 |
| HSP90R | TTGAGAAGGTCACCGTGTCG | |
| HERC4F | ACAGGTGGAGGGCTTAGGTT | 133 |
| HERC4R | CGGTGTGTTGGAAAACCTCT | |
| IRAK1F | GGCATCCCAACATAATGGAC | 119 |
| IRAK1R | GTTGCTGTCCTCACAGCGTA | |
| CXCR4F | ACCGTCATCCTCATCCTTTG | 86 |
| CXCR4R | ACGTTCAGCTCCACCAGAGT | |
| RasF | ACGACCCAACCATTGAGGAC | 131 |
| RasR | TCCGGTCCTCATGTACTGGT | |
| PI3KF | GATGGAGCCTTCCTCATCCG | 135 |
| PI3KR | CAAGTTGTAGGGCTCTGCGA | |
| AMPKF | TACCGTGCCATGAAACAGCT | 130 |
| AMPKR | GGTTGTCCACCTGGTAGAGC | |
| β-actinF | TGCAGTCAACATCTGGAATC | 191 |
| β-actinR | ATTTTTGGCGCTTGACTCAG |
Statistical data for sample sequencing.
| Sample | Read Number | Base Number | GC Content | % ≥Q30 |
|---|---|---|---|---|
| T01 | 36,262,497 | 10,633,672,216 | 47.49% | 89.44% |
| T02 | 28,349,442 | 8,398,124,460 | 47.15% | 89.57% |
| T03 | 28,251,699 | 8,299,768,760 | 48.54% | 89.91% |
| T04 | 29,010,341 | 8,549,124,730 | 47.87% | 90.09% |
Note: Samples: Sample name on the sample information sheet; Read number: Total number of paired-end reads in the clean data; Base number: Total number of bases in the clean data; GC content: GC content in the clean data, which is the percentage of G and C bases in the total bases in the clean data; % ≥Q30: Percentage of bases with a mass value ≥ 30 in the clean data.
Figure 2Unigene length distribution. The abscissa indicates the length of the unigene, and the ordinate indicates the number of unigene of a certain length.
Comparison of sequencing data and assembly results.
| Sample | Number of Clean Reads | Number of Mapped Reads | Mapped Ratio |
|---|---|---|---|
| T01 | 36,262,497 | 26,659,090 | 73.51% |
| T02 | 28,349,442 | 20,801,516 | 73.37% |
| T03 | 28,251,699 | 21,018,859 | 74.39% |
| T04 | 29,010,341 | 21,523,297 | 74.19% |
Note: Samples: Sample name on the sample information sheet; Clean reads: Number of clean reads, paired end; Mapped reads: Number of mapped reads, paired end; Mapped ratio: Percentage ratio of mapped reads in the clean reads.
Distribution of annotated unigenes.
| Anno_Database | Annotated_Number | 300 ≤ Length < 1000 | Length ≥ 1000 |
|---|---|---|---|
| COG_Annotation | 10,157 | 2887 | 6538 |
| GO_Annotation | 20,555 | 6433 | 12,164 |
| KEGG_Annotation | 21,915 | 7875 | 11,248 |
| KOG_Annotation | 27,599 | 9471 | 14,856 |
| Pfam_Annotation | 28,364 | 8584 | 17,552 |
| Swissprot_Annotation | 22,535 | 7054 | 13,358 |
| eggNOG_Annotation | 39,539 | 14,403 | 19,799 |
| nr_Annotation | 41,260 | 15,294 | 20,454 |
| All_Annotated | 42,522 | 15,898 | 20,572 |
Note: Annotated databases: the function of the database; Annotated_Number: Number of comments annotated to the unigene database; 300 ≤ Length < 1000: Number of unigenes annotated to the database that is ≤300 or less and <1000 bases in length; Length ≥ 1000: Number of unigenes annotated to the database that are >1000 bases in length.
Figure 3The number of differentially expressed genes. DEG Set: Name of differentially expressed gene set; All DEG: Number of differentially expressed genes; upregulated: TNumber of upregulated genes; downregulated: Number of downregulated genes.
Figure 4MA map of differentially expressed genes. Each point represents a gene in the MA map of differentially expressed genes. The abscissa is the A value: log2 (FPKM), the logarithm of the mean value of the expression in the two samples. The ordinate is the M value: log2 (FC), the logarithm of the difference in gene expression between the two samples, which was used to measure the difference in the level of expression. The green and red dots represent genes with significant differences in expression levels, green represents downregulated gene expression, red represents upregulated gene expression, and black spots represent genes with no significant differences in expression.
Figure 5Clustering map of differentially expressed genes Gene Ontology (GO) in test group and control group. The abscissa is the GO classification, on the left of the ordinate is the percentage of the number of genes, and on the right is the number of genes. This figure shows the secondary function of each GO gene enrichment status in the background of the differentially expressed genes and the background of all the genes, thus reflecting the status of each secondary function in two backgrounds. The secondary function with significant difference indicates that the differentially expressed genes are different from the enrichment trend of all genes, and can be focused on whether this function is related to the difference.
Figure 6Orthologous classification of the differentially expressed genes in the COG (Clusters of Orthologous Groups) database between the experimental group and the control group. The abscissa is the COG (Clusters of Orthologous Groups) content of each classification, and the ordinate is the number of genes. In different functional categories, the number of genes reflects the corresponding period and the environment under the metabolic or physiological biases and other content, and the object can be combined with the distribution of various functional classes to generate a scientific explanation.
Figure 7KEGG classification of differentially expressed genes. The ordinate is the name of the KEGG metabolic pathway, and the abscissa is the ratio of the number of genes annotated to the pathway and the number of genes in the annotated genes.
Statistical table of SSR analysis results.
| #Type | Number |
|---|---|
| c | 1556 |
| c * | 68 |
| p1 | 11,943 |
| p2 | 6079 |
| p3 | 2078 |
| p4 | 249 |
| p5 | 10 |
| p6 | 2 |
| Total | 21,985 |
Note: Total number of identified sequences: Total number of sequences evaluated: Total size of examined sequences (bp): Number of total bases evaluated; Total number of identified SSRs: Total number of SSRs identified; Number of SSR containing sequences: number of sequences containing SSRs; Number of sequences containing >1 SSR: Number of sequences containing >1 SSR and SSR overlaps each other; Number of SSRs present in compound formation: Number of SSRs in complex form; Mononucleotide: Single-base repeat SSR; Dinucleotide: Double-base repeat SSR; Trinucleotide: Three-base repeat SSR; Tetranucleotide: Four-base repeat SSR; Pentanucleotide: Five-base repeat SSR; Hexanucleotide: Six-base repeat SSR.
SNP distribution.
| Sample | HomoSNP | HeteSNP | AllSNP |
|---|---|---|---|
| T01 | 37,230 | 66,496 | 103,726 |
| T02 | 35,852 | 60,150 | 96,002 |
| T03 | 35,445 | 57,150 | 92,595 |
| T04 | 34,355 | 53,879 | 88,234 |
Figure 8Comparison of relative fold changes between RNA-seq and qRT-PCR results.
Representative immune-related genes that are differentially expressed after reovirus infection.
| Gene Name | Description | Change | log2FC | FDR |
|---|---|---|---|---|
| T-cell receptor signaling pathway | ||||
| Ras | GTPase HRas | Up | 1.84 | 0.000154 |
| SNARE interactions in vesicular transport | ||||
| VAMP4 | Vesicle-associated membrane protein 4 | Up | 1.68 | 0.005729 |
| Nicotinate and nicotinamide metabolism | ||||
| PNP | Purine-nucleoside phosphorylase | Up | 1.92 | 4.45 × 10−17 |
| NRK1_2 | Nicotinamide/nicotinate riboside kinase | Up | 1.61 | 4.37 × 10−6 |
| Phagosome | ||||
| ATPeV0A | V-type H+-transporting ATPase subunit a | Up | 1.67 | 6.01 × 10−9 |
| TUBB | Tubulin beta | Up | 2.17 | 1.48 × 10−6 |
| C1R | Complement component 1, r subcomponent | Down | −2.39 | 5.62 × 10−6 |
| ITGB2 | Integrin beta 2 | Down | −1.73 | 5.78 × 10−5 |
| MRC | Mannose receptor, C type | Up | 2.91 | 2.73 × 10−8 |
| Jak-STAT signaling pathway | ||||
| STAT1 | Signal transducer and activator of transcription 1 | Up | 1.62 | 6.02 × 10−5 |
| CBL | E3 ubiquitin-protein ligase CBL | Up | 2.28 | 0.007492469 |
| SHP-1 | Tyrosine-protein phosphatase non-receptor type 6 | Down | −2.54 | 5.79 × 10−7 |
| GRB2 | Growth factor receptor-binding protein 2 | Down | −1.74 | 5.42 × 10−5 |
| EP300 | E1A/CREB-binding protein | Up | 1.67 | 0.000264763 |
| CISH | Cytokine-inducible SH2-containing protein | Up | 3.38 | 4.58 × 10−30 |
| MYC | Myc proto-oncogene protein | Up | 3.49 | 9.21 × 10−29 |
| BCL2L1 | Bcl-2-like 1 (apoptosis regulator Bcl-X) | Up | 2.19 | 0.000500092 |
| Toll-like receptor signaling pathway | ||||
| PIK3C | Phosphatidylinositol-4,5-bisphosphate 3-kinase | Up | 3.73 | 7.41 × 10−32 |
| MYD88 | Myeloid differentiation primary response protein MyD88 | Up | 2.61 | 1.96 × 10−11 |
| IRAK1 | Interleukin-1 receptor-associated kinase 1 | Up | 2.49 | 1.63 × 10−22 |
| NFKBIA | NF-kappa-B inhibitor alpha | Down | −3.11 | 4.49 × 10−17 |
| MAP2K6 | Mitogen-activated protein kinase 6 | Down | −3.60 | 1.29 × 10−8 |
| P38 | p38 MAP kinase | Down | −3.04 | 5.50 × 10−10 |
| FOS | Proto-oncogene protein c-fos | Up | 2.30 | 6.13 × 10−6 |
| Cytokine-cytokine receptor interaction | ||||
| CXCR4 | C-X-C chemokine receptor type 4 | Down | −2.93 | 4.62 × 10−7 |
| CXCL14 | C-X-C motif chemokine 14 | Down | −1.65 | 1.04 × 10−12 |
| IL11 | Interleukin 11 | Up | 6.03 | 0.00595422 |
| CNTFR | Ciliary neurotrophic factor receptor | Down | −1.86 | 0.001965213 |
| LEP | Leptin | Down | −4.19 | 1.23 × 10−7 |
| LEPR | Leptin receptor | Up | 2.54 | 1.02 × 10−7 |
| EGFR | Epidermal growth factor receptor | Up | 2.22 | 5.09 × 10−5 |
| TNFRSF11B | Tumor necrosis factor receptor superfamily member 11B | Up | 4.86 | 9.75 × 10−40 |
| TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 | Up | 4.37 | 7.65 × 10−15 |
| Apoptosis | ||||
| TNFRSF10 | Tumor necrosis factor receptor superfamily member 10 | Up | 2.26 | 0.000275944 |
| MYD88 | Myeloid differentiation primary response protein MyD88 | Up | 2.26 | 0.000275944 |
| IRAK1 | Interleukin-1 receptor-associated kinase 1 | Up | 2.49 | 1.63 × 10−22 |
| MAP3K14 | Mitogen-activated protein kinase 14 | Up | 3.13 | 6.78 × 10−8 |
| PIK3C | Phosphatidylinositol-4,5-bisphosphate 3-kinase | UP | 3.73 | 7.41 × 10−32 |
| CAPN2 | Calpain-2 | Down | −1.60 | 6.44 × 10−9 |
| CFLAR | CASP8 and FADD-like apoptosis regulator | Up | 2.14 | 2.40 × 10−5 |
| BCL2L1 | Bcl-2-like 1 (apoptosis regulator Bcl-X) | Up | 2.19 | 0.000500092 |
| NFKBIA | NF-kappa-B inhibitor alpha | Down | −3.11 | 4.49 × 10−17 |
| XIAP | E3 ubiquitin-protein ligase XIAP | Up | 1.60 | 3.86 × 10−12 |
| CASP3 | Caspase 3 | Down | −2.28 | 1.94 × 10−14 |
| CASP9 | Caspase 9 | Up | 2.20 | 9.13 × 10−15 |
| mTOR signaling pathway | ||||
| PIK3R | Phosphoinositide-3-kinase, regulatory subunit | Up | 3.73 | 7.41 × 10−32 |
| PRKCA | Classical protein kinase C alpha type | Down | −1.69 | 1.46 × 10−7 |
| AKT1S1 | Proline-rich AKT1 substrate 1 | Down | −1.63 | 4.59 × 10−7 |
| AMPK | 5′-AMP-activated protein kinase, catalytic alpha subunit | Down | −2.06 | 0.000638513 |
Figure 9Significantly differentially expressed genes identified by KEGG that are involved in Toll-like receptor signaling pathway. Red boxes indicate upregulated DEGs; Green boxes represent downregulated DEGs; (For interpretation of colors used in this figure, please refer to the web version of this article).
Figure 10Significantly differentially expressed genes identified by KEGG that are involved in the cytokine-cytokine receptor interaction signaling pathway. Red boxes indicate upregulated DEGs; Green boxes represent downregulated DEGs; Blue boxes show no changes in expression. (For interpretation of colors used in this figure, please refer to the web version of this article).
Figure 11Significantly differentially expressed genes identified by KEGG that are involved in the Jak-STAT signaling pathway. Red boxes indicate upregulated DEGs; Green boxes represented downregulated DEGs; Blue boxes show no changes in expression. (For interpretation of colors used in this figure, please refer to the web version of this article).
Figure 12Significantly differentially expressed genes identified by KEGG that are involved in the NOD-like receptor signaling pathway. Red boxes indicate upregulated DEGs; Green boxes represented downregulated DEGs; (For interpretation of colors used in this figure, please refer to the web version of this article).